Compare Amylx Pharmaceuticals Inc (AMLX) vs Las Vegas Sands Corp. (LVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Las Vegas Sands Corp. — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while Las Vegas Sands Corp. trades at $46.6 (market cap $30.94B). The key difference: Las Vegas Sands Corp. is far larger — about 15.6× Amylx Pharmaceuticals Inc's market cap, and Las Vegas Sands Corp. pays a 2.36% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | LVS | |
|---|---|---|
Market Cap | $1.98B | $30.94B |
Sector | Health | Consumer Cyclical |
52-Week High | $18.70 | $69.49 |
52-Week Low | $7.64 | $46.06 |
Enterprise Value | $1.70B | $43.33B |
Dividend Yield | — | 2.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
LVS trades at $46.69, up 0.52% with a bearish technical signal despite strong fundamentals. The company demonstrates robust revenue growth, reaching $13.02B in 2025 with consistent earnings beats and a 13.41% net margin. Analyst consensus remains strongly bullish with a $66.89 price target, though technical indicators show selling pressure with support at $46.
LVS presents a compelling investment case with strong operational performance and analyst support, though technical weakness and high debt levels pose risks. The stock offers significant upside potential from current levels if fundamental strength continues, but investors should monitor debt management and Macau market conditions closely.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Las Vegas Sands Corp.
Las Vegas Sands is the world's largest operator of fully integrated resorts, featuring casino, hotel, entertainment, food and beverage, retail, and convention center operations. The company owns the Venetian Macao, Sands Macao, Londoner, Four Seasons Hotel Macao, and Parisian in Macao, and the Marina Bay Sands resort in Singapore. Its Venetian and Palazzo Las Vegas in the U.S. asets were sold to Apollo and VICI for $6.25 billion in 2022. We expect Sands to open a fourth tower in Singapore in 2026. After the sale of its Vegas assets, the company will generate all its EBITDA from Asia, with its casino operations generating the majority of sales.
Read more on LVS →
